No retraction, correction or concern found when last checked on Oct 16, 2026.
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Matthew R. Brier, Brian Gordon, Karl Friedrichsen and 13 more
Science Translational Medicine · 2016
doi:10.1126/scitranslmed.aaf2362
Abstract
PET imaging of pathological tau correlates more closely with Alzheimer’s disease–related cognitive impairment than does imaging of β-amyloid.
Shown for reading. Its publisher allows quoting it, not republishing it.
References 51
- 1.
Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387-403.
Not in our library10.1016/s0140-6736(06)69113-7
- 2.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
Not in our library10.1007/bf00308809
- 3.
Thal DR, Rüb U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-1800.
Not in our library10.1212/wnl.58.12.1791
- 4.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. Imaging brain amyloid in Alzheimer'sdisease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
Not in our library10.1002/ana.20009
- 5.
Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-452.
Not in our library10.1212/01.wnl.0000228230.26044.a4
- 6.
Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: Early progress and future directions. Lancet Neurol. 2015;14:114-124.
Not in our library10.1016/s1474-4422(14)70252-2
- 7.
Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science. 1992;256:184-185.
Not in our library10.1126/science.1566067
- 8.
Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216.
Not in our library10.1016/s1474-4422(12)70291-0
- 9.
Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Dominantly Inherited Alzheimer Network, Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
Not in our library10.1056/nejmoa1202753
- 10.
Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461:916-922.
Not in our library10.1038/nature08538
- 11.
Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: Time, space and ‘wingmen’. Nat Neurosci. 2015;18:800-806.
Not in our library10.1038/nn.4018
- 12.
Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, Morrison JH, Gold G, Hof PR. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60:1495-1500.
Not in our library10.1212/01.wnl.0000063311.58879.01
- 13.
Gómez-Isla T, Price JL, Mc Keel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491-4500.
Not in our library10.1523/jneurosci.16-14-04491.1996
- 14.
Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925-931.
Not in our library10.1212/01.wnl.0000115115.98960.37
- 15.
Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101-118.
Not in our library10.1385/jmn:17:2:101
- 16.
Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Gómez-Isla T. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787-800.
Not in our library10.1002/ana.24517
- 17.
Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: A voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126-2139.
Not in our library10.1093/brain/aws125
- 18.
Hampel H, Bürger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008;4:38-48.
Not in our library10.1016/j.jalz.2007.08.006
- 19.
Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412-2414.
Not in our library10.1212/wnl.43.11.2412-a
- 20.
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457-468.
Not in our library10.3233/jad-122059
- 21.
- 22.
Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, Bateman RJ, Cairns NJ, Aldea P, Cash L, Christensen JJ, Friedrichsen K, Hornbeck RC, Farrar AM, Owen CJ, Mayeux R, Brickman AM, Klunk W, Price JC, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Schofield PR, Buckles V, Morris JC, Benzinger TLS. Dominantly Inherited Alzheimer Network, Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015;107:55-64.
Not in our library10.1016/j.neuroimage.2014.11.058
- 23.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer'sdisease. Alzheimers Dement. 2011;7:280-292.
Not in our library10.1016/j.jalz.2011.03.003
- 24.
Jack CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765-775.
Not in our library10.1002/ana.22628
- 25.
Lockhart R, Taylor J, Tibshirani RJ, Tibshirani R. A significance test for the lasso. Ann Stat. 2014;42:413-468.
Not in our library10.1214/13-aos1175
- 26.
Tibshirani R. Regression shrinkage and selection via the lasso. J Roy Stat Soc B Met. 1996;58:267-288.
Not in our library
- 27.
Zou H, Hastie T. Regularization and variable selection via the elastic net. J Roy Stat Soc B. 2005;67:301-320.
Not in our library
- 28.
Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652-2663.
Not in our library10.1056/nejmoa054625
- 29.
Shin J, Lee SY, Kim SH, Kim YB, Cho SJ. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage. 2008;43:236-244.
Not in our library10.1016/j.neuroimage.2008.07.022
- 30.
Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Su H, Szardenings AK, Walsh JC, Wang E, Yu C, Zhang W, Zhao T, Kolb HC. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666-676.
Not in our library10.1016/j.jalz.2012.11.008
- 31.
Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain. 2011;134:1089-1100.
Not in our library10.1093/brain/awr038
- 32.
Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171-184.
Not in our library10.3233/jad-130098
- 33.
Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VMY, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094-1108.
Not in our library10.1016/j.neuron.2013.07.037
- 34.
Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137(Pt. 6):1762-1771.
Not in our library10.1093/brain/awu064
- 35.
Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2014;41:816-826.
Not in our library10.1007/s00259-013-2681-7
- 36.
Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ. Functional connectivity: The principal-component analysis of large (PET) data sets. J Cereb Blood Flow Metab. 1993;13:5-14.
Not in our library10.1038/jcbfm.1993.4
- 37.
Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Nat Neurosci. 1998;1:355-358.
Not in our library10.1038/1565
- 38.
Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Aβ, tau, and α-synuclein: Acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30:7281-7289.
Not in our library10.1523/jneurosci.0490-10.2010
- 39.
Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med. 2010;4:51-63.
Not in our library10.2217/bmm.09.83
- 40.
Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M. Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re2.
Not in our library10.1126/scitranslmed.3006446
Cited by papers we hold 27
- Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography · 2023No notice
- Screening for Core Genes Related to Pathogenesis of Alzheimer’s Disease · 2021Not checked
- Higher cerebrospinal fluid tau is associated with history of traumatic brain injury and reduced processing speed in Vietnam‐era veterans: A Department of Defense Alzheimer's Disease Neuroimaging Initiative (DOD‐ADNI) study · 2021Not checked
- Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy · 2021Not checked
- Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals · 2021No notice
- Early-Onset Alzheimer’s Disease: What Is Missing in Research? · 2021No notice
- Applying surface-based morphometry to study ventricular abnormalities of cognitively unimpaired subjects prior to clinically significant memory decline · 2020Not checked
- Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease · 2020No notice
- Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected · 2020No notice
- Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease · 2020No notice
- Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework · 2019No notice
- [18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series · 2019Not checked
- A walk through tau therapeutic strategies · 2019No notice
- Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity · 2019Not checked
- Tau PET imaging in neurodegenerative tauopathies—still a challenge · 2019No notice
- Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age · 2019No notice
- Mechanisms of secretion and spreading of pathological tau protein · 2019No notice
- Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research · 2019No notice
- Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer’s disease pathology and cognitive symptoms · 2019No notice
- Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue · 2019No notice
and 7 more
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.